Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations

被引:94
|
作者
Arendrup, Maiken Cavling [1 ]
Perlin, David S. [2 ]
Jensen, Rasmus Hare [1 ]
Howard, Susan Julie [3 ]
Goodwin, Joanne [3 ]
Hope, William [3 ]
机构
[1] Statens Serum Inst, Unit Mycol & Parasitol, DK-2300 Copenhagen, Denmark
[2] UMDNJ New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ USA
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester, Lancs, England
基金
美国国家卫生研究院;
关键词
INVASIVE CANDIDIASIS; REDUCED SUSCEPTIBILITY; AMPHOTERICIN-B; ALBICANS; TROPICALIS; ECHINOCANDINS; SUBSTITUTIONS; EPIDEMIOLOGY; ESOPHAGITIS; FLUCONAZOLE;
D O I
10.1128/AAC.06369-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half-and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg . h/liter, respectively. In contrast, the maximum effect (E-max) for caspofungin was higher against S3 than R83, but the estimates for E-50 were similar (187.1 and 203.5 mg . h/liter, respectively). Anidulafungin failed to induce a >= 1-log reduction for any of the isolates (AUC range, 139 to 557 mg . h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.
引用
收藏
页码:2435 / 2442
页数:8
相关论文
共 50 条
  • [31] Development of echinocandin resistance after in vitro micafungin exposure in clinical isolates of Candida glabrata
    Rivero-Menendez, O.
    Navarro-Rodriguez, P.
    Alastruey-Izquierdo, A.
    MEDICAL MYCOLOGY, 2018, 56 : S53 - S53
  • [32] Absence of FKS1 and FKS2 mutations in Caspofungin resistant C. glabrata isolates from candidemia patients in Delhi, India
    Prakash, A.
    Singh, A.
    Chowdhary, A.
    MYCOSES, 2015, 58 : 70 - 70
  • [33] Comparison of Antimycotic Activity of Originator and Generics of Voriconazole and Anidulafungin against Clinical Isolates of Candida albicans and Candida glabrata
    Nussbaumer-Proell, Alina Karoline
    Eberl, Sabine
    Welte, Rene
    Gasperetti, Tiziana
    Marx, Jana
    Bellmann, Romuald
    Zeitlinger, Markus
    JOURNAL OF FUNGI, 2022, 8 (02)
  • [34] Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin:: Analysis and proposal for interpretive MIC breakpoints
    Pfaller, M. A.
    Diekema, D. J.
    Ostrosky-Zeichner, L.
    Rex, J. H.
    Alexander, B. D.
    Andes, D.
    Brown, S. D.
    Chaturvedi, V.
    Ghannoum, M. A.
    Knapp, C. C.
    Sheehan, D. J.
    Walsh, T. J.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (08) : 2620 - 2629
  • [35] Characterising the post-antifungal effects of micafungin against Candida albicans, Candida glabrata, Candida parapsilosis and Candida krusei isolates
    Nguyen, Katherine T.
    Ta, Philip
    Hoang, Bich Thu
    Cheng, Shaoji
    Hao, Binghua
    Nguyen, M. Hong
    Clancy, Cornelius J.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (01) : 80 - 84
  • [36] Set of Classical PCRs for Detection of Mutations in Candida glabrata FKS Genes Linked with Echinocandin Resistance
    Dudiuk, Catiana
    Gamarra, Soledad
    Leonardeli, Florencia
    Jimenez-Ortigosa, Cristina
    Vitale, Roxana G.
    Afeltra, Javier
    Perlin, David S.
    Garcia-Effron, Guillermo
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (07) : 2609 - 2614
  • [37] In vitro activities of caspofungin and ketoconazole against Iranian isolates of Candida albicans
    Abad, H. Shekari Ebrahim
    Zaini, F.
    Kordbacheh, P.
    Mahmoudi, M.
    Safara, M.
    Mortezaee, V.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 : E327 - E327
  • [38] In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates
    Angeles Bordallo-Cardona, Maria
    Escribano, Pilar
    de la Pedrosa, Elia Gomez G.
    Judith Marcos-Zambrano, Laura
    Canton, Rafael
    Bouza, Emilio
    Guinea, Jesus
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (02)
  • [39] Frequency of fks Mutations among Candida glabrata Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates
    Castanheira, Mariana
    Woosley, Leah N.
    Messer, Shawn A.
    Diekema, Daniel J.
    Jones, Ronald N.
    Pfaller, Michael A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) : 577 - 580
  • [40] Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1
    Balashov, Sergey V.
    Park, Steven
    Perlin, David S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) : 2058 - 2063